A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Opicinumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms AFFINITY
- Sponsors Biogen
- 01 Aug 2017 Planned End Date changed from 27 Nov 2020 to 13 Apr 2021.
- 01 Aug 2017 Planned primary completion date changed from 16 Sep 2020 to 20 Dec 2020.
- 01 Aug 2017 Planned initiation date changed from 18 Oct 2017 to 28 Sep 2017.